Benjamin Greenberg

17.4k total citations · 4 hit papers
212 papers, 9.6k citations indexed

About

Benjamin Greenberg is a scholar working on Pathology and Forensic Medicine, Neurology and Immunology. According to data from OpenAlex, Benjamin Greenberg has authored 212 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Pathology and Forensic Medicine, 81 papers in Neurology and 38 papers in Immunology. Recurrent topics in Benjamin Greenberg's work include Multiple Sclerosis Research Studies (106 papers), Peripheral Neuropathies and Disorders (57 papers) and Systemic Lupus Erythematosus Research (20 papers). Benjamin Greenberg is often cited by papers focused on Multiple Sclerosis Research Studies (106 papers), Peripheral Neuropathies and Disorders (57 papers) and Systemic Lupus Erythematosus Research (20 papers). Benjamin Greenberg collaborates with scholars based in United States, Germany and Canada. Benjamin Greenberg's co-authors include Michael Levy, Dean M. Wingerchuk, J. de Sèze, Jeffrey L. Bennett, Kazuo Fujihara, Elliot M. Frohman, Brian G. Weinshenker, Anthony Traboulsee, Tanuja Chitnis and Brenda Banwell and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Benjamin Greenberg

196 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

2015 3.0k citations Dean M. Wingerchuk, Brenda Banwell et al. Neurology profile →
Genetic progression model for head and neck cancer: implications for field cancerization.

1996 1.1k citations Benjamin Greenberg et al. profile →
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

2019 415 citations Takashi Yamamura, Ingo Kleiter et al. profile →
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

2020 317 citations Anthony Traboulsee, Benjamin Greenberg et al. profile →

Peers

Countries citing papers authored by Benjamin Greenberg

Since Specialization

Citations

This map shows the geographic impact of Benjamin Greenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Greenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Greenberg more than expected).

Fields of papers citing papers by Benjamin Greenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Greenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Greenberg. The network helps show where Benjamin Greenberg may publish in the future.

Co-authorship network of co-authors of Benjamin Greenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Greenberg. A scholar is included among the top collaborators of Benjamin Greenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Greenberg. Benjamin Greenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study 2025 ·Neurology Neuroimmunology & Neuroinflammation ·Jeffrey L. Bennett, Kazuo Fujihara, Albert Saiz, Anthony Traboulsee, Benjamin Greenberg, Brian G. Weinshenker, Francesco Patti, Ingo Kleiter, Jacqueline Palace, J. de Sèze, Rachael A Evans, Kathleen Blondeau, Gaëlle Klingelschmitt, (unknown), (unknown), Takashi Yamamura	1
2	Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study 2025 ·Neurology Neuroimmunology & Neuroinflammation ·Jeffrey L. Bennett, Kazuo Fujihara, Albert Saiz, Anthony Traboulsee, Benjamin Greenberg, Brian G. Weinshenker, Francesco Patti, Ingo Kleiter, Jacqueline Palace, J. de Sèze, Rachael A Evans, Kathleen Blondeau, Gaëlle Klingelschmitt, (unknown), (unknown), Takashi Yamamura	1
3	AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient 2024 ·Nature Medicine ·James J. Dowling, (unknown), (unknown), (unknown), (unknown), (unknown), Mustafa Şahin, Darius Ebrahimi‐Fakhari, (unknown), G. S. Varadarajan, Benjamin Greenberg, (unknown), Berge A. Minassian, Ronald D. Cohn, Carsten G. Bönnemann, Steven J. Gray	11
4	Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder 2024 ·Journal of the Neurological Sciences ·Anisha M. Patel, (unknown), Irina Yermilov, (unknown), Sarah N. Gibbs, (unknown), (unknown), (unknown), Michael S. Broder, Stanley Cohan, Benjamin Greenberg, (unknown)	1
5	Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study 2023 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Peter V. Sguigna, (unknown), (unknown), Kyle Blackburn, (unknown), Darrel Conger, (unknown), R. Nick Hogan, Morgan McCreary, Phyllis C. Zee, Joseph S. Takahashi, Benjamin Greenberg	1
6	VH2+ Antigen-Experienced B Cells in the Cerebrospinal Fluid Are Expanded and Enriched in Pediatric Anti-NMDA Receptor Encephalitis 2023 ·The Journal of Immunology ·Nancy Monson, (unknown), (unknown), Patricia Plumb, (unknown), (unknown), Chen Ding, Wei Zhang, (unknown), Haley E. Speed, Craig M. Powell, (unknown), Lindsay G. Cowell, Scott Christley, Steven Vernino, Kyle Blackburn, Benjamin Greenberg	0
7	Determining Prevalence of Depression and Covariates of Depression in a Cohort of Multiple Sclerosis Patients 2022 ·SHILAP Revista de lepidopterología ·(unknown), Morgan McCreary, (unknown), Benjamin Greenberg	4
8	Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience 2022 ·Neuro-Ophthalmology ·Peter V. Sguigna, (unknown), Kyle Blackburn, (unknown), Darrel Conger, R. Nick Hogan, Morgan McCreary, Benjamin Greenberg	1
9	Cryptococcal Meningitis Reported With Fingolimod Treatment 2022 ·Neurology Neuroimmunology & Neuroinflammation ·Maurizio Del Poeta, Brian J. Ward, Benjamin Greenberg, Bernhard Hemmer, Bruce Cree, (unknown), Jitendriya Mishra, (unknown), (unknown), Alan Moore, Thomas Hach, Joseph R. Berger	17
10	A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse 2022 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Benjamin Greenberg, James D. Bowen, Enrique Álvarez, Moses Rodriguez, Anthony O. Caggiano, Arthur E. Warrington, Ping Zhao, Andrew Eisen	7
11	COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients 2021 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), (unknown), Bernhard Hemmer, Bruce Cree, Benjamin Greenberg, Uma Kundu, Thomas Hach, (unknown), Brian J. Ward, Joseph R. Berger	25
12	Pediatric paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian teratoma 2021 ·Multiple Sclerosis Journal ·(unknown), Cynthia Wang, Veena Rajaram, Benjamin Greenberg	4
13	Efficacy and safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): Results from open-label extension periods of SAkuraSky and SAkuraStar 2021 ·Investigative Ophthalmology & Visual Science ·Zdenka Hašková, Benjamin Greenberg, Jeffrey L. Bennett, Brian G. Weinshenker, Anthony Traboulsee, Michael R. Yeaman, Kristina Weber, Kathleen Blondeau, H.‐Christian von Büdingen, Daniela Stokmaier, Gaëlle Klingelschmitt	1
14	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study 2020 ·Multiple Sclerosis Journal ·Tanuja Chitnis, Brenda Banwell, Lauren Krupp, Douglas L. Arnold, Amit Bar‐Or, Wolfgang Brück, Gavin Giovannoni, Benjamin Greenberg, Angelo Ghezzi, Emmanuelle Waubant, Kevin Rostásy, Kumaran Deiva, Peter Huppke, Jerry S. Wolinsky, Ying Zhang, (unknown), (unknown), (unknown), Jutta Gärtner	7
15	Efficacy of Satralizumab (SA237) in Subgroups of Patients in SakuraSky: A Phase III Double-Blind, Placebo-Controlled, Add-On Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) 2020 ·Multiple Sclerosis Journal ·Tomohiko Yamamura, Ingo Kleiter, (unknown), Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska‐Pniewska, F. Patti, (unknown), Albert Saiz, Masayuki Haramura, Yukihiro Terada, Yuichi Kawata, J. de Sèze	1
16	A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD) 2018 ·Multiple Sclerosis Journal ·J. de Sèze, Ingo Kleiter, (unknown), Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska‐Pniewska, Francesco Patti, (unknown), Ana Sáiz, Yukihiro Terada, Yuichi Kawata, Pádraig Wright, (unknown)	5
17	CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics 2016 ·The Journal of Immunology ·Chen Ding, Sara Ireland, Gina Remington, Enrique Álvarez, Michael K. Racke, Benjamin Greenberg, Elliot M. Frohman, Nancy Monson	41
18	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders breakdown → 2015 ·Neurology ·Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett, Philippe Cabre, William M. Carroll, Tanuja Chitnis, J. de Sèze, Kazuo Fujihara, Benjamin Greenberg, Anu Jacob, Sven Jarius, Marco Aurélio Lana–Peixoto, Michael Levy, Jack H. Simon, Silvia Tenembaum, Anthony Traboulsee, Patrick Waters, Kay E. Wellik, Brian G. Weinshenker	2985
19	Associations between retinal nerve fiber layer abnormalities and optic nerve examination 2010 ·Neurology ·Deanna Cettomai, Girish Hiremath, John N. Ratchford, Arun Venkatesan, Benjamin Greenberg, (unknown), Carlos Pardo, Douglas A. Kerr, Elliot M. Frohman, Laura J. Balcer, Justin C. McArthur, Peter A. Calabresi	16
20	Deep Brain Stimulation for Psychiatric Disorders 2002 ·Neurosurgery ·Bart Nuttin, J. Gybels, Paul Cosyns, Loes Gabriëls, (unknown), (unknown), Steven A. Rasmussen, Benjamin Greenberg, Gerhard M. Friehs, Ali R. Rezai, Erwin B. Montgomery, (unknown), Joseph J. Fins	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact